

IN THE SPECIFICATION

(1) Delete paragraph [30] and replace it with:

FIG. 5. aAPC-induced Mart-1 CTL recognize endogenous antigen on melanoma target cells. Mart-1 specific CD8⁺ cells were obtained after *in vitro* culture with Mart-1 loaded aAPC. Mart-1-specific T cells were stimulated with either a Mart-1⁺/HLA-A2⁻ melanoma cell line (1st column) or with a Mart-1⁺/HLA-A2⁺ Melanoma cell line (2nd column). For the ICS staining the cells were incubated with melanoma cells in regular medium without cytokines. To elevate the baseline, a low dose of PMA and Ionomycin was added to the medium. After one hours, Monensin (GOLGISTOPTM, a protein transport inhibitor Golgi-stop) was added to the culture. After six hours, the T cells were harvested and analyzed by intracellular cytokine staining. The percentage of peptide-specific, IL-4⁺/CD8⁺ T cells is shown.

(2) Delete paragraph [168] and replace it with:

In a representative experiment the total number of T cells increased from 1 x 10⁶ to 20 x 10⁶ in the DC-induced cultures and from 1 x 10⁶ to 14 x 10⁶ in the aAPC induced cultures. Antigenic specificity of the culture was analyzed after 3 weeks by both A2-Ig dimer staining and ICS. In our hands, ICS staining can be up to twice as sensitive as dimer staining, due possibly to heterogeneity in the induced CTL population. ICS will detect a broader population of high and low affinity CTL than dimer staining. Cells were stained with FITC-conjugated CD8 mAb and Mart-1-pulsed A2-Ig as described. For ICS cells were incubated with peptide-pulsed T2 cells in regular medium without cytokines. After 1 h, Monensin (GOLGISTOPTM, a protein transport inhibitor Golgi-stop) was added to the culture. After 6h the T cells were harvested and analyzed by ICS. The percent of peptide-specific CD8⁺ CTL is shown in the upper right corner.